
Excessive Daytime Sleepiness
Latest News


Orexin Agents ORX750 and ORX142 Show Promising Early Phase 1 and 2 Data

World Narcolepsy Day: Raising Awareness for Earlier Recognition and Management
Latest Videos
CME Content
More News

Deepa Burman, MD, FAASM, co-director of the Pediatric Sleep Evaluation Center at UPMC Children’s Hospital of Pittsburgh, discussed the potential contributors to pediatric insomnia and the role of a thorough assessment for effective management.

A recent analysis reveals the safety profile of once-nightly sodium oxybate for narcolepsy, highlighting low discontinuation rates and common adverse events.

A new study evaluates the effectiveness and safety of once-nightly sodium oxybate for narcolepsy, aiming to enhance patient treatment experiences.

A phase 2 study shows samelisant significantly reduces excessive daytime sleepiness in narcolepsy, paving the way for further research and development.

Recent findings from an analysis showed that sodium oxybate significantly reduced narcolepsy symptoms, including cataplexy and excessive daytime sleepiness, among patients with the sleep disorder.

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.

Over the 6-month treatment period, patients saw improvements in cataplexy frequency, excessive daytime sleepiness, cognition, and work productivity with AXS-12.









